Scholarlink

Inroduction <p>Chemoradiation with cisplatin is the standard of care in locally advanced cervical cancers. There are many factors, which do not allow cisplatin to be administered concurrently with radiation. The objective of this pilot study is to evaluate the efficacy and safety of capecitabine-based chemoradiotherapy in cisplatin-ineligible cervical cancer patients.</p> Materials and Methods <p>Patients received oral capecitabine 825&#xa0;mg/m2 twice daily (5&#xa0;days/week) along with concurrent external beam radiation 50.4&#xa0;Gy, followed by high dose rate (HDR) brachytherapy. Patients were reassessed for clinical response at 12&#xa0;weeks of completion of treatment. The toxicities were assessed using common toxicity criteria.</p> Results <p>Twelve patients with squamous cell carcinoma of uterine cervix were included in this study. Five patients were stage II, six were stage III and one patient was stage IV.A. Ten patients had a complete response. One patient had a partial response, and one patient had progressive disease with lung metastases after external radiation. There were no grade III or grade IV toxicities.</p> Conclusion <p>Our study suggests that capecitabine is well tolerated along with pelvic radiation in cervical cancer patients. Simple daily convenient oral administration of drug is more likely to be accepted by the patients. Also further trials of concurrent capecitabine along with radiation therapy in cervical cancer patients are merited.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Pilot Study to Assess the Efficacy and Safety of Capecitabine-Based Chemoradiotherapy for Cisplatin-Ineligible Patients with Squamous Cell Carcinoma of the Uterine Cervix

  • 期刊论文

  • 发表日期：

    2025年10月6日

查看全文
  • Dinesh Sundararajan,
  • Vengada krishnan,
  • Gopika Rajeev,
  • Vasanth Christopher Jayapaul,
  • Perumal Kalaiyarasi Jayachandran,
  • Venkatraman Radhakrishnan,
  • Manikandan Dhanushkodi,
  • Ram Madhavan

摘要

Inroduction

Chemoradiation with cisplatin is the standard of care in locally advanced cervical cancers. There are many factors, which do not allow cisplatin to be administered concurrently with radiation. The objective of this pilot study is to evaluate the efficacy and safety of capecitabine-based chemoradiotherapy in cisplatin-ineligible cervical cancer patients.

Materials and Methods

Patients received oral capecitabine 825 mg/m2 twice daily (5 days/week) along with concurrent external beam radiation 50.4 Gy, followed by high dose rate (HDR) brachytherapy. Patients were reassessed for clinical response at 12 weeks of completion of treatment. The toxicities were assessed using common toxicity criteria.

Results

Twelve patients with squamous cell carcinoma of uterine cervix were included in this study. Five patients were stage II, six were stage III and one patient was stage IV.A. Ten patients had a complete response. One patient had a partial response, and one patient had progressive disease with lung metastases after external radiation. There were no grade III or grade IV toxicities.

Conclusion

Our study suggests that capecitabine is well tolerated along with pelvic radiation in cervical cancer patients. Simple daily convenient oral administration of drug is more likely to be accepted by the patients. Also further trials of concurrent capecitabine along with radiation therapy in cervical cancer patients are merited.